Evidence map›Paper›PMID 36542584›Full record

ArticleRevista de la Facultad de Ciencias Medicas (Cordoba, Argentina)2022

[Creatine phosphokinase enzyme elevation in two third-level hospitals of Córdoba].

Emanuel José Saad, Andrés Rodríguez Ruiz, Augusto Douthat Y Barrionuevo, Martín Milanesio, Janet Flores Balverdi, Nadia Claudine Riscanevo, Gabriela Estefanía Peñaranda, Elisa Beatriz Novatti, Verónica Saurit, Ana Cecilia Alvarez and 1 more

Open access · diamondAbstract readEnglish Abstract
In one paragraph

Article in Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Emanuel José SaadHospital Privado universitario de Córdoba. emanuelsaad@hotmail.com.
Andrés Rodríguez RuizHospital Privado Universitario de Córdoba. rodriguezruizandresn@gmail.com.
Augusto Douthat Y BarrionuevoHospital Privado Universitario de Córdoba. douthataug@gmail.com.
Martín MilanesioHospital Privado Universitario de Córdoba. mmilanesio5@gmail.com.
Janet Flores BalverdiHospital Privado Universitario de Córdoba. janelabaly@hotmail.com.
Nadia Claudine RiscanevoHospital Privado Universitario de Córdoba. naclaurisca@hotmail.com.
Gabriela Estefanía PeñarandaHospital Privado Universitario de Córdoba. gabypenarandasd@gmail.com.
Elisa Beatriz NovattiHospital Privado Universitario de Córdoba. elisanovatti@gmail.com.
Verónica SauritHospital Privado Universitario de Córdoba. vsaurit@gmail.com.
Ana Cecilia AlvarezHospital Privado Universitario de Córdoba. cecialvarez72@gmail.com.
Diego Federico BaenasHospital Privado Universitario de Córdoba. baenashospitalprivado@gmail.com.
Hospital Privado · AR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: HyperCKemia is defined as the elevation of creatine phosphokinase (CK) levels greater than 1.5 times the upper limit (CK>285 U/L), being produced by multiple causes, which vary according different populations. The main objective of the study was to know the frequency of hyperCKemia in two hospitals in Córdoba and its main causes. Methods: Retrospective analytical study in two hospitals in Córdoba, Argentina, where all patients over 18 years of age who presented CK values ​​greater than 285 U/L on at least 2 occasions in a period between 1 and 4 weeks were identified, between the years 2015 and 2017. Results: 254 patients with hyperCKemia were identified, the majority were male (n=181, 71.3%) and their median age was 65 years (interquartile range 25-75%=50-73 years). The main causes of hyperCKemia were ischemic myopathy in 99 (39%) patients and drug-induced myopathies in 45 (17.7%), with statins being the most frequently involved drugs in 31 cases. In only 3.1% of the cases the final diagnosis was not reached. Drug-induced hyperCKemias, when compared to other causes, occurred more frequently in patients with a history of chronic kidney disease (9/45 [20%] vs 18/209 [8.6%], p = 0.025) and in non-smokers (41/45 [91.1%] vs. 157/209 [75.1%], p=0.019). Main conclusion: 254 cases of hyperCKemia were observed, the main causes being of ischemic origin and secondary to drug use, especially statins.

Indexed as

Hydroxymethylglutaryl-CoA Reductase InhibitorsRenal Insufficiency, ChronicAdolescentAdultCreatine KinaseFemaleHospitalsHumansMaleRetrospective StudiesCreatine KinaseHydroxymethylglutaryl-CoA Reductase Inhibitorscreatine phosphokinaseinflammationmuscular diseasesmyositis

Identifiers

PMID36542584
PMCPMC9987303
OpenAlexW4312114033

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.